A fixed-dose combination (FDC) medication designed for the symptomatic relief of common cold, allergic rhinitis, and associated conditions. It combines a mucolytic (Ambroxol), a second-generation antihistamine (Levocetirizine), an analgesic-antipyretic (Paracetamol), and a nasal decongestant (Phenylephrine). This combination addresses multiple symptoms simultaneously: cough with thick mucus, nasal congestion, sneezing, runny nose, headache, body ache, and fever. It is widely prescribed in India for upper respiratory tract infections and allergic conditions.
Adult Dosage: One tablet twice daily. Maximum: 2 tablets in 24 hours. Should be taken after food with a full glass of water.
Instructions: Oral administration. Swallow whole with water, do not crush or chew. Best taken after meals to minimize gastric irritation. Maintain adequate hydration to aid ambroxol's mucolytic action. Do not take for more than 5 days for fever or 3 days for pain without medical advice.
The combination exerts a multi-targeted symptomatic effect. Ambroxol stimulates surfactant production and serous secretion in the respiratory tract, breaking down acid mucopolysaccharide fibers in sputum. Levocetirizine is a potent and selective peripheral H1-receptor antagonist, inhibiting histamine-mediated allergic symptoms. Paracetamol acts centrally by inhibiting cyclooxygenase (COX) enzymes, particularly in the CNS, reducing prostaglandin synthesis involved in pain and fever. Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction in the nasal mucosa, reducing edema and congestion.